Abstract
Ovarian cancer is a common malignant tumor in gynaecology and its mortality rate is the highest in gynecological cancer. Ovarian cancer patients should face platinum resistance, caused by multiple recurrences. According to the platinum-free interval (PFI), recurrent ovarian cancer can be divided into platinum-resistant (PFI<6 months) and platinum-sensitive (PFI≥6 months). When PFI is 6-12 months, it belongs to the partial platinum-sensitive ovarian cancer. At present, how to prolong the survival of patients with partial platinum-sensitive recurrent ovarian cancer is difficult. Secondary cytoreductive surgery, non-platinum chemotherapy, anti-angiogenesis drugs, and molecular targeted therapy of poly (ADP ribose) polymerase (PARP) inhibitors can improve the prognosis of patients with partial platinum-sensitive recurrent ovarian cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
